Advertisement

Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria

  • Deepa A. Malieckal
  • Frank Modersitzki
  • Kristin Mara
  • Felicity T. Enders
  • John R. Asplin
  • David S. GoldfarbEmail author
Original Paper

Abstract

Appropriate dosing of cystine-binding thiol drugs in the management of cystinuria has been based on clinical stone activity. When new stones form, the dose is increased. Currently, there is no method of measuring urinary drug levels to guide the titration of therapy. Increasing cystine capacity, a measure of cystine solubility, has been promoted as a method of judging the effects of therapy. In this study, we gave increasing doses of tiopronin or d-penicillamine, depending on the patients’ own prescriptions, to ten patients with cystinuria and measured cystine excretion and cystine capacity. The doses were 0, 1, 2, 3 g per day, given in two divided doses, and administered in a random order. Going from 0 to 1 g/day led to an increase in cystine capacity from − 39.1 to 130.4 mg/L (P < 0.009) and decreased 24 h cystine excretion from 1003.9 to 834.8 mg/day (P = 0.039). Increasing the doses from 1 to 2 to 3 g/day had no consistent or significant effect to further increase cystine capacity or decrease cystine excretion. Whether doses higher than 1 g/day have additional clinical benefit is not clear from this study. Limiting doses might be associated with fewer adverse effects without sacrificing the benefit of higher doses if higher doses do not offer clinical importance. However, trials with stone activity as an outcome would be desirable.

Keywords

Alpha-mercaptopropionylglycine Aminoaciduria, renal Calculi, renal d-Penicillamine Renal tubular transport, Inborn errors Tiopronin 

Notes

Acknowledgements

The Rare Kidney Stone Consortium (U54DK083908-01) is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS and NIDDK. This consortium is funded through collaboration between NCATS, and the NIDDK. We are also deeply grateful to Litholink for performance of urine testing. We also appreciate the continued support of the International Cystinuria Foundation, which has consistently encouraged our work.

Compliance with ethical standards

Conflict of interest

Malieckal: none; Modersitzki: none; Mara: none; Enders: none; Asplin: employee, Litholink Corp; Goldfarb: consultant, Retrophin; funding from NIDDK, NCATS.

References

  1. 1.
    Sumorok N, Goldfarb DS (2013) Update on cystinuria. Curr Opin Nephrol Hypertens 22(4):427–431CrossRefGoogle Scholar
  2. 2.
    Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136(5):1003–1008CrossRefGoogle Scholar
  3. 3.
    Barbey F, Joly D, Rieu P, Mejean A, Daudon M, Jungers P (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163(5):1419–1423CrossRefGoogle Scholar
  4. 4.
    Coe FL, Clark C, Parks JH, Asplin JR (2001) Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol 166(2):688–693CrossRefGoogle Scholar
  5. 5.
    Goldfarb DS, Coe FL, Asplin JR (2006) Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int 69(6):1041–1047CrossRefGoogle Scholar
  6. 6.
    Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS (2005) Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol 19(3):429–432CrossRefGoogle Scholar
  7. 7.
    Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL (2000) Clinical use of cystine supersaturation measurements. J Urol 164(5):1481–1485CrossRefGoogle Scholar
  8. 8.
    Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL (1999) Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 56(4):1505–1516CrossRefGoogle Scholar
  9. 9.
    Nakagawa Y, Coe FL (1999) A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. Clin Chim Acta 289(1–2):57–68CrossRefGoogle Scholar
  10. 10.
    Rosenberg LE, Durant JL, Holland JM (1965) Intestinal absorption and renal extraction of cystine and cysteine in cystinuria. N Engl J Med 273(23):1239–1245CrossRefGoogle Scholar
  11. 11.
    Netter P, Bannwarth B, Pere P, Nicolas A (1987) Clinical pharmacokinetics of D-penicillamine. Clin Pharmacokinet 13(5):317–333CrossRefGoogle Scholar
  12. 12.
    Carlsson MS, Denneberg T, Emanuelsson BM, Kagedal B, Lindgren S (1993) Pharmacokinetics of oral tiopronin. Eur J Clin Pharmacol 45(1):79–84CrossRefGoogle Scholar
  13. 13.
    Carlsson MS, Denneberg T, Emanuelsson BM, Kagedal B, Lindgren S (1994) The pharmacokinetics of tiopronin as such is unknown. Eur J Clin Pharmacol 46(6):576–577CrossRefGoogle Scholar
  14. 14.
    Friedlander JI, Antonelli JA, Canvasser NE, Morgan MSC, Mollengarden D, Best S, Pearle MS (2018) Do urinary cystine parameters predict clinical stone activity? J Urol 199(2):495–499CrossRefGoogle Scholar
  15. 15.
    Goodman JW, Asplin JR, Goldfarb DS (2009) Effect of two sports drinks on urinary lithogenicity. Urol Res 37(1):41–46CrossRefGoogle Scholar
  16. 16.
    Goldfarb DS, Asplin JR (2001) Effect of grapefruit juice on urinary lithogenicity. J Urol 166(1):263–267CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Deepa A. Malieckal
    • 1
  • Frank Modersitzki
    • 2
  • Kristin Mara
    • 3
  • Felicity T. Enders
    • 3
  • John R. Asplin
    • 4
  • David S. Goldfarb
    • 2
    • 5
    Email author
  1. 1.Division of Nephrology, Department of MedicineHofstra Northwell School of MedicineHempsteadUSA
  2. 2.Nephrology DivisionNYU Langone Medical CenterNew YorkUSA
  3. 3.Biomedical Statistics & InformaticsMayo ClinicRochesterUSA
  4. 4.Litholink Corp, Laboratory Corporation of America® HoldingsChicagoUSA
  5. 5.Nephrology DivisionNew York University Langone Health and New York Harbor VA Healthcare SystemNew YorkUSA

Personalised recommendations